thank for and us joining and all for second you Good conference update corporate results afternoon call. quarter Therapeutics Thank XXXX you, Ian. Sarepta
for date. moment As we mid us our on pass through to progress let a year, linger
to an RNA prove and XXXX significant much entered still execution platform. set we requiring the path we As ambitious for with
new PMO contention. for in community truly with but Duchenne populations the and bring to we're other efficacious for continue controversy RNA drive FDA [ph] and we the therapies, one have the consistently would creating necessary to new pathway the that of and performance, treatments new rapidly constructs approval So without been efficient forged of excellent
XX results initial we our platform truly programs we've the gene For therapy through gene and gene discovered meet micro-dystrophin other with that we've the therapy plus the therapy seen of possess. any
therapy we out of in we micro-dystrophin. where manufacturing vivo gene for the for commercial the sort our and landscape of resources, ahead micro-dystrophin build for developed talent, process a to and others micro-dystrophin gene competitive of itself qualitatively One completed energy For XX remain the in the placebo-controlled therapy. patients [indiscernible] quickly trial necessary we the dosing
we continuous questions some Over we our of the than The course in we quarter these of is more August the just golodirsen simply have PDUFA not entered one in as the first It ways the XXXX have positive, for could FDA XX. and positive to answers year. anticipated filing accepted have been perform. date rightly to
we XX which development and pathways if We have to meeting as obtain biotech. advisory also will will not approval month a approval a sufficient in it of approval by have August predicate committee and rapid our
Duchenne our we success FDA into the our for PMO replicate precision for of XXXX, Showing platform, platform through evidence further in results segments positive we we our announced to population. the next the platform, if to and submit successful ability in RNA and generation first quarter review consistency have is three that and it the our PPMO of greater intend casimersen
announced And our first really cohort the has ligand lead or the of results gene therapy internal our [indiscernible] the positive. landscape quarter in first In the platform as therapy [indiscernible] of program. known first for been gene program positive we XXXX
nature Dr. Gene Columbus Excellence the the same engine. same the As of consistency in world of and Louise exceptional Therapy promoter these our further and our programs vector, share results class of The the therapy that validated Ohio. our of many gene work Center Rodino-Klapac
in Nationwide in from our our Children's with XXXX. results that Dr. promised the partner, announced half A only study one XX remarkable proof first Mendell of concept ago. considers when patients placebo-controlled feat we our we one trial all of Jerry As in Hospital, year of about dosed micro-dystrophin
be credible well. we but As companies the with appeared programs we two as other micro-dystrophin in to advancing lead, entered XXXX
disclosed a intends that on protocol program is to effort amount show while for delays those Pfizer both Xx has results programs, initial more it reviews signals dose expression for from in disappointing ethics expression an have quantifiable resulting announced in hold both a an those results. mandated and Unfortunately they [indiscernible] programs and recently programs profoundly of terms patients to and that have unfortunately of committee initial its been of escalate both safety levels, suffered and its
So as compared itself to XXXX, to in appear have would in from others, appears probably early it success. program and time, micro-dystrophin Sarepta’s the in this distanced of landscape at of substance, the at stage start further
position not risks our be while Indeed changing longer we no further case. does to we obligation we falsely the the of that One our bolster program with how presents could and in our need such an community. this is to placebo from leadership we be this but this will current with that that shortly opportunity landscape discuss in give believe a the sense and urgency, both might trial it manufacturing, enhanced us of doing Sarepta move to will leaves
so is competitor muscular have shared, disease space real in Duchenne his dystrophy. the we often As itself, only our
this fully battle hope a we the for informed which of must everyday hold you this invariably with are real and alone then possibility make their effectively. thousands As and we lost a can very transformative tens disease operate and with know, by now decisions of work the children make energy muscle decisions The and that responsibility. treatment of and we [indiscernible] realized have we we are
let's continued out review that at last Starting decisions RNA quarter quarter have very quarter the performance in same million the EXONDYS quarter of some recent we a year that, made. in $XX.X second XX%. with to with standing and sales So the franchise, perform, over growth and impressive XX
golodirsen way mentioned XXXX. August I often is be VYONDYS the will forward. golodirsen date using this now for I as XX, XX, so of other PMOs is By our name going For name brand the PDUFA the
are immediately just We approval. launch ready to upon VYONDYS
approval boitechs an with first will which more internally expected developed that, we rare a synergies. by we for living launched more an of of very We this than group or with and be three we will will But developed the has one number If have more than patients decision also submit of of the early successful, are XXXX XXXX. therapy. Duchenne double who year in casimersen available PMO half have
study Our next is initiated an SRP-XXXX. RNA proceeding ascending PPMO the dosing generation multi-arm a at dose for program, in
of and by XXXX. is to goal insight safety obtain Our dosing first the half
therapy we have significant and year progress our second gene Now half of this made the first to franchise, moving on the quarter.
patients this As work dosing a blinded, Mendell, the trial, Jerry impressive we Dr. X. placebo-controlled in noted that trial earlier, call have completed Study XXX all of XX or Study call of through I we
may study from Children's material with conducted recall, Nationwide this Hospital. being As clinical is you
Our internal sufficiently proof of in to sized statistical analysis should study suggests one be treatment our year. and see cohort of effect a first concept a review that this
However, case Children's it by the Hospital. this material the from also study is that amount available study dictated of Nationwide was
increase from Children's study we XX of protocol study additional able study that to pleased by nearly We are to have that and basis very Nationwide XX to provide material increasing the on to patients, the with Hospital XX%. been the the us has amended announce study size
we the in rapid site plan to Dr. over of patients, enrollment additional open in increase and significantly the the confidence should the XX% the able to year. this To study clinical also fourth Mendell level. power enrollment will in initial another we these trial to very between dosing of near This U.S. complete term, site aid we believe quarter and be
add With the Study still X end readout XXXX. before increased of should the
from ensure at power of very study decision of in material best as available NCHS we we the to is increase is greater XX% robust compelling. Now this and my increase once straightforward possible. the to was power reasonable have interests the to all this that study trial patients it least than perspective and
We of XXXX no trial this was changed over justify of environment and [ph]. clinical to failing course pressure external journal to competitive the has much that acknowledge advantage take there also simply exogenous the
latest is that confidence. study in there in changed nothing powering that certainly our assumptions our and is The who so For either has we of unblinded original sort very will XXX - Study well. blinded nothing seen to and any and know changes performed is doubt we you as in have need we perform any XXX have analysis. continue to unblinded Study it nor
of opportunity We taking to are an in X. Study increase success simply of advantage probability the
XXXX. commence less in remainder our of we X is of commercial increasing plan XXXX will use development the – commence of Study so this and process process instead the to half in Study began pressure there first continue to in light optimizing to for and study In we X supply the XXXX,
of still by our be remind readout commercial been using to Study data a from has process to As our goal, three-month intended Study X. we have Study supply. you, plan X study To biopsy X is the
topic capacity. that on to make and very continue On on commercial progress process good we
end Our be it commercial will year. complete, August this is the October in facility of about about by qualified Lexington it completed and just be should by
We in yields and date. achieve of are scaling is units very and in to to process iCellis working yields have up the units, the achieved in that commercial optimized very our good going nano XXX iCellis we well and
on are analytical good development. progress We making
but could reasons. to reasonably commercial Study have the supply date, prudent not commencing Based number that of do a we XXXX, for time simply work by with us to given so the available additional it on we end the done to have X anticipated is of
that be creates and to we gene launching plan for this Sarepta. or at As of launched. have landscape change that the possibility alone noted, planning in gene we a must yields have likely is this optimized ensure and the alone We will satisfy a DMD we least very advantage process significant significant for we competitive micro-dystrophin we're needs must for increasingly potentially therapy the the means responsibility
process To to continue intend we yields. end, to improve and that
and risk If would to of having continue yield thereafter you as lock improve we process intention, unnecessary to the the our early be and commence process to X X run would bridging Study risk the between competitive today. in light ultimate an landscape of conduct yet is unacceptable supply. the another and commercial study show the comparability Study the and to This timelines supply artificially
We the most and obligation we is by our informed with are external [indiscernible]. landscape program taking by communities the to approach importantly micro-dystrophin our are
further to placebo of current we material the improve advantage and study the First, additional going to trial our of success. probability powering of to are enhance take
regardless when to the requirements yield going commercial are with we are to to take available the to the maximize and we the alone that the We of process position the DMD with community access time us satisfy for rapid serve. the support success goal regardless of we evidence are of and building in country we the on age, to goal of the X and ambulatory citizenship. Duchenne And of are regardless protocol or is Study status, providing regardless patients mutation sufficient designed of
now, let's gene on to So move other our therapy programs.
patients excellent pro supply in Nationwide of E first using positive Hospital our will we one to three the of cohort escalation predefined you, XX% the was cohort our real and either five obtained his to and XXX% dosing To Limb-girdle [ph] year. milestone success cohort times prior additional Following dose of study. remind results we XX fibers be Children's gene the
had We we Western and also had mean XX%. qualification intensity of Blot of an XX% impressive mean
Myonexus one will We year. also Limb-girdle With higher two out cohort will five up that the manufacturing early chart pivotal we on we next Paragon, you back a for possible and three based our pathway at dose to we for then of trial. report dose patient programs doses all will choose will the for partner our additional and between results a
syndrome, With of MPS our neurological treat to also disease devastating therapy have of that Dr. commence with a children Charcot-Marie-Tooth gene Hospital. the before the we known IIIA, far dosed year are Sahenk Nationwide so Phase seven or the in in life material the our X/X partner age obtain Sanfilippo XX. our working program end Children's at to Lysogene, dosing as before robs patients we CMT And of to program
genetic end, that to We square gene to our disease. our facility instituted are have rare Toward properly therapy team in also therapy in taken vision XX,XXX world's ensure building an of leader XXXX the that become course over we the Columbus, Ohio. significant foot steps gene and
We also acres. our XX in Andover, expanded footprint Massachusetts XX have from acres to
our that iCellis some in in use we tolerance space analytical additional significant taken taking units [ph] process have in to addition activity. Burlington, Massachusetts we facility, have space Square we solely XX where Kendall for In
This Massachusetts. completion single is foot our near There will Lexington, commercial therapy to square dedicated XX,XXX supply. gene of micro-dystrophin in use a be facility site
Lexington capacity We out that more at we at and have also facility. the capacity have Paragon grand taken we in our have additional sufficient at Paragon double fact than to space
We have a business been also not sitting idle development from perspective.
for begin a into entered we technology have and discuss as We partnerships focus. from we clinical advance more licenses into that detail important to pre-clinical in number will new eight of
include For [indiscernible]. these instance
University school advance fatal We girls. Miguel novel treat Green, have Rett Syndrome, the into leaders, with a exclusively Michael that to entered Gao, therapy Medical variable Massachusetts a Guangping of the partnership and Sena-Esteves, Drs. gene and gene nearly to rare disease brain affects and therapy
agreement We the [indiscernible] advance of treatment Dr. of University with have therapy into Medicine the also and to for entered an of College gene cardiomyopathy. Florida
gene therapy Our treat muscle. disease ending and skeletal has a Columbus of life X, that Excellence Emery-Dreifuss built and therapy affects type limiting gene to often innovative muscular at Center dystrophy rare an life [indiscernible] neuromuscular cardiac
advancing Emery-Dreifuss rapidly muscular University our Worman, program. and to We Dr. world's Howard in us of the leader Emery-Dreifuss assist have collaboration entered with in study dystrophy the into a Columbia
very treatments is of Research rich beyond every I importantly, advance Head development and XX,XXX most affects and and year. remind Hoffman's Gilmore into in Dr. focus, And program of with to This may have X of And our this some Dr. a the seem approval core people very the of that sclerosis, of therapy while Development, of agreement you the affecting responsible each rare area deaths MS. that background Medicine a entered innovative for to to disorder O'Neill Brad mediated treat venture as the the would worldwide plus successful our outside central million first common exciting College has immune and University novel system. diseases and for is about we nervous multiple gene Florida, our
tools also Center are providing of therapy additional We for gene our Excellence.
have our into the PPMOs Massachusetts assist also with into Dr. the to Lab we in Biology and University of Gao Institute a instance, relationship development exploration to with derived have school and we entered Medical human of micro-dystrophin. of And of entered vectors. For a collaboration novel the a the of Guangping combination
our resources the we are were are and have we our fully we end to plans. we XXX by Today about accomplished seasoned of this Sarepta, And to many employees most dedicated is of a commercial among senior the today. I of employees genetic XXX joined on leader XXX genetic employees. and in group When tracking integrated medicine It execute year. are nearly stage, approximately medicine the
billion also the to end develop QX well of are of As resourced cash. we $X.X in
of have we XXXX for our and well the we in much foot we on gone and to in not. have things Although take and do accelerator the first leadership cannot XXXX half year, our will stick position granted. the We'll
of For dose EXONDYS We for the to month optimization, this approved of development must be in first half the the must remainder XX. process we our analytical X. XX the XXXX. VYONDYS a our must enroll and Study yield development We of work increased continue continue to and position dosing must in and remainder serve this year. XXXX casimersen of submit and XX if community We with rapidly commence
all must or next [indiscernible] our on must programs. out to we cohort of of therapy first our increasing dose gene CMT and and our remainder for our advance Limb-girdle dose We our must ever of the gene plans and of genetic build therapy pipeline. build medicine Charcot-Marie-Tooth We our cohort engine continue
in I mission. to to for for I would this And this participating their hardworking who mission, in like and in mention employees for with to thank the clinical Mendell, families also micro-dystrophin us a their who to rare believe step have passion special opportunity thank thank working to disease partners Sarepta. program like to with taken dedication would to and tirelessly this like take [indiscernible] would Dr. collaboration who of advance our their with trials the clinic. our is all and very I Jerry to dedication of our also the
to is requires studies it to the we're is dedication. It children rare of advance benefit can even unapproved it of families programs but our about as we thousands our lucky and decide around world of our the trials easy families their the ultimately of Much asked thousands, look in quality be few, participating in tens and families is trial it, in that upon gene mistake fighting. that through living therapy courage participation with hundreds make the to your trials no requires of perhaps and in those for diseases
I'll over turn update with call the that, And provide Sandy to Sandy? an to our financials. on
